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S_mary The qualitative and quantitative importance of tamoxifen (TMX) metabolism in vivo led us to
investigate further the metabolic profile of this major anti-oestrogenic drug in a significant group of 81 breast
cancer patients and to evaluate the respective in vitro activity of each metabolite. TMX and its four
metabolites described until now (NDT, 4-OHT, Y, Z) were measured in blood (HPLC method) at the time of
first drug intake and at the steady state. Between these two states, the unchanged drug relative proportion
dropped from 65% to 27%. Demethylation was the major metabolic pathway. For 13 clinically evaluable
patients, there was no significant difference in the distribution of serum levels of TMX and metabolites as a
function of response to treatment. In vitro studies were performed on two human breast cancer cell lines:
MCF-7, oestrogen receptor and progesterone receptor positive (ER+, PR+) and CAL-18 B (ER-, PR-).
Cytostatic effects were evaluated by the tritiated thymidine incorporation test. TMX and all metabolites were
active on these two cell lines, but the 50% inhibitory concentrations (IC 50) were 4-250-fold higher in CAL-
18 B than in MCF-7, depending on the metabolite considered. For the MCF-7 cells only, the anti-
proliferating activity was parallel to the relative binding affmity for ER. Moreover, for the MCF-7 cells only,
the effects of these drugs were partially reversed by oestradiol (E2), the higher the metabolite affinity for ER,
the lower the reversal efficacy. These compounds were tested in mixtures at proportions duplicating those
found in patients after initial drug intake (mixture Dl), and the steady state (mixture Css). The mixtures were
also compared to the equimolar unchanged drug. No differences were seen among these three experimental
conditions for either MCF-7 or CAL-18 B. A dose-effect relationship was noted. Overall, TMX and its
metabolites exert a dual effect when concentrations are below a threshold between 2 x 10-6 and 10-5 M, the
drugs are mainly cytostatic; this effect is related to their affinity for ER. At higher relevant clinical
concentrations, a cytotoxic activity is observed and it appears independent of the presence of ER.
Tamoxifen (TMX) is one of the most widely used form of
endocrine therapy for patients with breast cancer (Furr &
Jordan, 1984). Several trials have established the importance
of this agent in delaying relapse (Baum et al., 1985) and in
significantly prolonging survival (Fischer et al., 1987). It is
generally recognised that breast cancer patients with positive
oestradiol (E2) and progesterone (P) receptors (R) respond
better to TMX than those with negative receptors. But there
are both clinical (Baum et al., 1985; Vogel et al., 1987) and
experimental (Miller et al., 1984; Katzenellenbogen et al.,
1985) data which suggest that the effects of TMX on tumour
growth should not be considered as merely an inhibition of
the action of oestrogens. Several reports have pointed out
the quantitative (Adam et al., 1980; Kemp et al., 1983) and
qualitative (Wakeling & Slater, 1980; Jordan, 1984) impor-
tance of TMX metabolism for the expression ofdrug activity
in vitro.
Up to now four metabolites have been identified in
patients: N-desmethyltamoxifen (NDT), 4-hydroxytamoxifen
(4-OHT) and the more recently described metabolites Y
(Jordan et al., 1983) and Z (Kemp et al., 1983). In a recent
study (Milano et al., 1987) we described on a limited number
of patients an updated metabolic profile of TMX in plasma.
Marked differences were observed between the beginning of
treatment and the time steady state was reached (one month
or more of continuous TMX administration). Considering
that the mechanism of action of TMX is still poorly
understood (Rochefort, 1987) it seemed appropriate to re-
evaluate the importance of TMX metabolism in the expres-
sion of drug activity in vitro. To our knowledge, no such
unified study including TMX, NDT, 4-OHT, Y and Z has
been reported until now. However, significant contributions
concerning in vitro effects of TMX, NDT, 4-OHT (Reddel et
al., 1983) and Y (Jordan et al., 1983) have been published.
An attempt to reach the present objective necessitated
extension of our initial pharmacokinetic investigation to a
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larger population (81 patients). This made it possible to
characterise accurately the respective proportions of TMX
and metabolites at the beginning of treatment and at steady
state. On this clinically relevant basis, the activity of each
metabolite was tested in vitro on a set of human breast
cancer cells in culture (with and without E2R or PR). Thus
TMX and metabolites were considered both separately and
in mixtures corresponding to the exact average proportions
found in patients at the beginning of treatment and at steady
state.
Materials and methods
The structures
Figure 1.
of TMX and metabolites are presented in
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Figwe 1 Chemical structure of TMX and metabolites.
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Pharmacokinetic study
The study involved a group of 81 patients, mean age
65.6+12 years with advanced breast cancer without evolutive
hepatic lesions. TMX was given orally at the daily dosage of
30mg on a continuous basis. The kinetic profile upon first
drug intake (Dl) was done for 12 patients; blood was
sampled at the following times: 1,2,4,6,12,24h after drug
intake. Seventy-eight patients were monitored for blood
levels at steady state (at least one month of continuous
intake); blood samples were obtained at 8-9a.m., before the
daily dose of TMX. TMX (ICI 46 474), NDT (ICI 55 548),
4-OHT (ICI 79280), metabolites Y (ICI 142269) and
Z (ICI 142 268) were provided by ICI (Pharmaceuticals
Division, Macclesfield, UK). The internal standard,
Clomifene (CMF), was provided by Merrel Laboratories
(Panrs, France). Stock solutions of drugs (5x 1O-3M) were
prepared in absolute ethanol and stored in polyethylene
tubes at -20^C.
Analytical conditions have been described elsewhere in
detail (Milano et al., 1987). Briefly, the system consisted of
chromatographic separation on a CN HPLC column, on-line
photocycisation with a u.v. lamp, spectrofluorimetric
detection (4A=258nm, i,=378nm) and recording. Plasma
(O.5ml) spiked with 2OylCMF2x 1O-4M was extracted
twice with 4 volumes of diethyl ether each time. The
recoveries were TMX 67%, NDT 92%, Y 95%, Z 62% and
4-OHT 68%. Intra and inter-assay reproducibility were
respectively (CV%): TMX 3 and 14, NDT 2 and 10, Y 3
and 7, Z 7 and 11, 4-OHT 10 and 11. The sensitivity limit of
the method (considered as 2.5 times the baseline height) was
TMX3nM, NDT4nM, Y4nM, Z6nm, 4-OHT5nM.
Pharmaco-clinical correlations
Among the 81 patients treated by TMX, we selected those
treated by TMX only, i.e. without other associated oncologic
treatment, and whose lesions were objectively measurable.
This was done to try to correlate response to TMX
treatment with drug and metabolites blood levels, as
measured within the month after treatment response
assessment. According to this strict selection, only 13 of the
81 patients were analysed; nine had progressive disease, one
stabilised disease and three partial responses. Responses were
evaluated according to UICC criteria (Hayward et al., 1978).
The comparison of respective blood concentrations of
TMX and metabolites according to the treatment response
was done using the Mann-Whitney non-parametric test.
In vitro study
Relative binding affinities (RBAs) To determine the ability of
TMX and metabolites to compete for E2R, a constant
concentration of 3H-E2 (5nM) was incubated for 16h at 0°C
on a pool of E2R positive cytosols from human breast
cancers (mean value=42fmolmg protein-1; Milano et al.,
1983). There were increasing concentrations of ligands
(unlabelled E2, TMX and metabolites, 10-10 to 10-I M).
Data were plotted as percentage of tracer bound versus log
ligand concentration and the relative binding affinities
(RBAs) of TMX and metabolites were defined as
RBA=(CE2/CX) x 100, with CE2=concentration of E2
which displaces 50% of tracer bound and Cx=concentration
of ligand (TMX or metabolites) which displaces 50% of
tracer bound. On this basis the respective RBAs were
E2 100, 4-OHT 65, TMX 0.25, NDT 0.21, Z 0.17, Y 0.06.
Drug activity on cell lines Two established human breast
cancer cell lines were used: MCF-7 (E2Rt=30,
PR=785fmolmg protein-') was generously supplied by Pr
A. Rochefort (Montpellier, France) and CAL 18B (Gioanni
et al., 1985) a cell line obtained in our institute. CAL 18B
was considered as negative in both E2R (2fmolmg
protein-1) and PR (llfmolmg protein-1).
Cell lines were maintained in DMEM medium (Gibco,
Paisley, UK) supplemented with 5% fetal bovine serum
(Seromed, Biochrom KG, Berlin), 600pg1- insulin,
5mgl-1 transferrin, 5mM glutamine, 160mgl-1 genta-
mycin, 50,OOOLUI1 penicillin, 50,OOOpg -1 streptomycin.
The final E2 concentration in the medium was below
10- "M. Cells were incubated at 37-C in a humidified
atmosphere of 5% CO2 in air. Cells were suspended in 24-
well plates (Falcon 3047, Beckton Dickinson, Lincoln Park,
NJ, USA). Distributions were made in quadruplicate or
sextuplicate depending on the protocol conditions. Initial
conditions were 7,000-12,000 cells per well in 400p of
medium. After cell adhesion (24-48h) the medium was
removed and a medium supplemented with drug(s) was
added. TMX and metabolites were tested between 2 x 10-8
and 10-SM. Activity of TMX and metabolites was also
evaluated at 5 x 10 -M in presence (8 days co-incubation) of
E2 5 x 10-9, 5 x 10-8 and S x 10-7 M. Medium was renewed
daily until the end of experimentation (6-9 days). Dilutions
of TMX and metabolites were made from the stock solution
in ethanol by successive dilutions in the medium, so that the
final alcohol concentration in the medium did not exceed
0.2%; we tested that alcohol had no effect on cell
proliferation at this concentration. At the end of the fixed
incubation period, wells were washed with Medium 199 with
Hepes (Gibco, Paisley, UK). Cells were then incubated with
the same medium supplemented with 5% fetal bovine serum
and tritiated thymidine (1.4pCiml-1) for 16h. Cells were
then washed three times with cold PBS Medium (Gibco,
Paisley, UK) and precipitated with cold TCA 10% (w/v) for
30min. After removal of TCA, denaturated cells were solu-
bilised with I NNaOH and the solution was neutralised with
6NHCI. Radioactivity was measured on a Packard Tricarb
460. Cytostatic effects were quantified as percentage of
radioactivity per well as compared with controls without
drugs. Cytotoxic effect was evaluated by morphometry and
by loss of adhesion to the support. IC50 was defined as the
drug concentration causing 50% inhibition of cell growth,
with reference to untreated control cells.
Metabolic activity ofcell lines Media containing 2 x 10-6 M
of compound (TMX and/or metabolites) were incubated in
presence of MCF-7 and CAL-18 B cells (200,000 cells per
25cm2 flask) for 2-3 days. Controls without cells were run
in parallel. After the incubation period, media were collected
and analysed by HPLC to evaluate the drug profiles. Five
hundred p1 of medium was extracted by 2 x 2ml diethyl ether
and HPLC was performed as described above. The
percentage of remaining concentration was expressed as
follows: (C cells/C control) x 100, where C cells=
concentration of drug(s) in presence of cells and C control =
concentration of initial drug in control medium at the same
time and without cells.
Resuls
Pharmacokinetic study
Pharmacokinetic profles in treatedpatients Figure 2 shows
the time-concentration profile of TMX and metabolites after
the first oral dose (30mg) for 12 patients with breast cancer.
4-OHT excepted, all metabolites were present in blood from
the first hour and respective plasmatic peaks occurred
between 4 and 6h. Seventy-eight patients were explored for
blood TMX and metabolites once steady state was
considered as reached (one month or more). Table I gives
the mean concentrations and the respective proportions of
TMX and related species at the first dose (in terms of
percentages of total AUCO-24h) and at the steady state (in
terms of percentages of total plasmatic concentration). It
appears that a large inter-patient variability exists for the
individual capacity to produce metabolites and particularly
4-OHT, which had the highest coefficient of variation.
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Figwe 2 Initial kinetics of TMX and metabolites after 30mg
per os. Vertical bars indicate standard deviations (12 patients).
Filled square, TMX; open square, NDT; filled triangle, Y; open
triangle, Z; star, 4-OHT.
Between the first dose and steady state there is a striking
difference in the relative proportions of TMX, NDT and
metabolite Z. Desmethylation (TMX to NDT and NDT to
Z) seems to be the major route of TMX metabolism. We
observed, in 30% of patients, a well charactensed but non-
identified plasmatic metabolite, eluting just before 4-OHT
and thus slightly more polar than 4-OHT. Its peak height
was always higher than that of 4-OHT.
Clinicalpharmacokinetic correlations Figure 3 represents,
for the 13 evaluable patients receiving TMX alone, the
distribution of serum levels of TMX and metabolites
according to treatment response. There were no significant
differences between progressive disease, PD (nine patients)
Table I Mean concentrations and respective proportions of TMX
and metabolites at the first drug intake (initial kinetic, TMX 30mg
per os, 12 patients) and at the steady state (at least one month of
continuous TMX therapy, 30mg per os daily, 78 patients)
Frst drug intake (DI) Steady state (Css)
Cmax(nm) AUC O-24h(%) Css(nM) Css %
Mean+sd. Mean+sd. Mean+s-d. Mean+sd.
TMX 167+50 64.7+5.8 467+290 27.2+7.0
NDT 41+14 27.9+8.6 1,060+636 61 2+6.7
Y 14+11 4.6+4.3 71+79 4.1+3.5
Z 7+5 2.4+20 135+129 7.1+4.2
4-OHT <5 0.4+0.7 5+10 0.4+1.1
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Figwe 4 Effects of TMX and metabolites on MCF-7 cells.
Vertical bars represent standard deviations (sextuplets). Filled
square, TMX; open square, NDT; filled triangle. Y; open
triangle, Z; star, 4-OHT.
and stabilised (one patient) plus partial response, PR (three
patients) for all compounds tested. 4-OHT was quantifiable
in 50% of cases and the patient with the highest
concentration progressed under treatment; however this
patient had a negative ER status.
In vitro study
Individual activity of TMX and metabolites Figure 4 shows
the dose-response curves of each compound on MCF 7 cells
(E2R and PR positive). Globally, -for TMX and all
metabolites, the proliferation rate was reduced as a function
of drug concentration in medium. 4-OHT was the most
active and metabolite Y the least. At IC50, the order of
growth-inhibiting activity was as follows: 4-OHT>
NDT>TMX>Z>Y. For 4-OHT only, an additional cyto-
toxic effect was observed at all doses. For TMX, NDT and
Z, cytotoxicity was only evident at 10-5M. Metabolite Y
was never cytotoxic. On MCF7, the growth-inhibiting
activity of TMX and metabolites was generally parallel
to the RBAs for E2R (see Materials and methods).
Figure 5 shows the dose-response curves of each product
on CAL 18B cells (E2R and PR negative). A marked
growth-inhibiting effect of TMX and metabolites was evident
at a concentration range superior to that observed for
MCF 7 cells. Here, TMX was the most active, 4-OHT and
NDT the least; at IC5O, the order of activity for all products
was TMX>Y>Z>4-OHT=NDT. However, the differences
in ICSO between TMX and metabolites were hardly
evaluable. All drugs, except metabolite Y, were cytotoxic at
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Fugue 3 Repartition of TMX and metabolites at steady state as
a function of clinical response. Filled circles, partial responders
and stabilised; open circles, progressive disease. For 4-OHT,
there were in addition two cases of partial response and
stabilised with no detectable levels and five cases of progressive
disease with no detectable levels.
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F*we 5 Effects of TMX and metabolites on CAL 18-B cells.
Vertical bars represent standard deviations (sextuplets). Filled
square, TMX; open square, NDT; filled triangle, Y; open
triangle, Z; star, 4-OHT.
(Mlo
ll . 1
I---
r
u, muw
Ir,, - 1
ITAMOXIFEN METABOLISM 33
C
0
._
0
-
o C
o
I
C
0
C
ii
0
U 0
0-
C
0
4-
0
C;
100
75
50
25
C
0
._
-
C._
C
0
-
o
C)
0
U
0
0
cL
C 0
u
0
MCF7
/D
0
L
Co o0a
0 75 o CL
0 C
0 -
0
X s 25
I
L-n
v 1 10 100
Controls Oestradiol concentration (nM)
10 100 1,000
Drug concentration (nM)
1l000
Fgwe 7 Effects of TMX and metabolites 5 x 10-7M Co-
incubated with E2 5 x 10-9, 5 x 0-8 and 5 x10-7 M, on MCF-7
cell line. Vertical bars represent standard deviations (sextuplets),
Open circle, E2 alone; filled square, TMX; open square, NDT;
filled triangle, Y; open triangle, Z; star, 4-OHT.
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TaMe H Percentage of metabolites recovered after
incubation (3 days) in presence of MCF-7 cells as compared
to incubations without cells
Incubated drug TMX NDT Y Z 4-OHT
TMX 71
NDT - 89 - - -
Y - - 87 _ _
Z - - 45 78 -
4-OHT - - - - 81
Drug concentration (nM)
Figwe 6 Effects of drug mixtures in proportions representing
Dl and Css on MCF-7 and CAL-18 B cell lines. See text for
respective percentages of each drug. Vertical bars represent
standard deviations (sextuplets). Filled square, TMX; filled
circle, Dl; open circle, Css.
Activity ofmetabolites in mixture According to the pharma-
cokinetic results, the respective proportions of TMX and
metabolites tested, corresponded to those shown in Table I:
Dl, TMX=64.5, NDT=28, Y=4.5, Z=2.5, 4-OHT=0.5;
Css, TMX=27.5, NDT=61, Y=4, Z=7, 4-OHT=0.5.
Figure 6 shows the dose-response curves obtained on
MCF-7 and CAL-18 B cells for both TMX and drug
mixtures in proportions corresponding to D1, as compared
to those of Css. On MCF-7 cells, for all concentrations
tested, Dl and Css showed a similar efficacy which was also
globally comparable to TMX alone. Against CAL-18 B, Dl
and Css mixtures were also equipotent and more efficient
than TMX alone. Here again for a comparable effect, MCF-
7 required a lower concentration range than CAL-18 B.
Effect ofE2 On CAL-18B cells, E2 had no influence
against the growth inhibiting effects of TMX and
metabolites. In contrast (Figure 7), a concentration-
dependent reversal effect of E2 was noted on MCF-7 cells;
with E2 and drugs being equimolar (5x 10-7M) the effects
of metabolites Y and Z were completely reversed, TMX and
NDT partially reversed, and 4-OHT the least affected.
Metabolic activity ofcell lines Media were tested by HPLC
to determine if any drug biotransformation occurred in the
presence of cells as compared with controls (drugs incubated
with medium alone). It was possible to individualise the
transformation of metabolite Z into Y for both MCF-7 and
CAL-18 B. Table H gives the respective proportions of
recovered drugs after 3 days of contact with MCF-7 cells; a
significant percentage of metabolite Y was formed from
metabolite Z. This in vitro transformation was not found in
the absence of cells.
Disassi
The aim of this study was to evaluate the quantitative and
qualitative importance of TMX metabolism by both in vivo
and in vitro investigations. All metabolites reported so far
(Furr & Jordan, 1984) were included in this study. Lien et al.
(1988) recently described 4-hydroxy-N-desmethyltamoxifen as
a new TMX metabolite present in human bile; it was not
considered in our analysis but it is quite possible that its
physico-chemical nature corresponds to the unidentified
polar metabolite observed in our study. Mechanism of action
of TMX is far from simple. Apart from the direct effect of
TMX via E2R, there are numerous interactions with cellular
targets: binding to the so-called but still unidentified anti-
oestrogenic binding sites different from E2R (Miller et al.,
1984), induction of TGF-f (Knabbe et al., 1987), inhibition
of calmodulin (Gulino et al., 1986) and phospholipid/calcium
dependent protein kinase (Su et al., 1985). These data must
be recalled when discussing TMX activity.
A complete metabolic study of TMX was undertaken on a
large set of patients with special attention paid to the
elaboration of precise drug profiles at Dl and Css. All
metabolites considered could be detected at the first drug
intake. Confirming initial data (Wakeling & Slater, 1980)
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and our preliminary pharmacokinetic observations (Milano
et al., 1987), NDT was the major compound present in
blood at the steady state; 4-OHT was quantitatively the
minor metabolite but with a large inter-patient variability.
The heretofore less explored metabolites Y and Z may be
considered as being significantly present in blood. We
considered the steady state reached after at least 4 weeks of
continuous treatment, which is justified for TMX, but NDT
steady state is obtained later, after 8 weeks (Furr & Jordan,
1984). From Dl to Css, the parallel increase in proportion of
demethylated metabolites (NDT and Z) leads to the
conclusion that demethylation may be a major route of
TMX metabolism in human. These pharmacokinetic
observations constituted the clinically relevant basis for
comparing TMX and metabolite activity in vitro.
Dose-response curves obtained on breast cancer cell lines
with E2R (MCF-7) and without E2R (CAL-18 B) call up
several comments. It was striking to note that the order of
potency of the five products tested against MCF-7 cells was
comparable to that of their RBAs for E2R. This confirms
and extends the work of Reddel et al. (1983) where, against
MCF-7, 4-OHT was 100-167-fold more potent than both
TMX and NDT in producing dose-dependent decreases in
cell proliferation rate. This was also correlated with their
RBAs for E2R. These data taken together are in line with a
specific anti-oestrogenic effect of TMX and metabolites via
the E2R system. But results obtained on the E2R negative
cell line CAL-18 B modulate this conclusion and indicate
that TMX and metabolites, at a higher concentration range,
may be active in the absence of E2R. In this case, their order
of efficacy did not parallel their RBAs for E2R, and in
contrast with the results for MCF-7, 4-OHT was the least
active. In addition, E2 co-incubated with TMX and/or
metabolites reversed the drugs' effects only for E2R positive
cels.
In a comparable study, but limited to TMX, Reddel et al.
(1985) observed that E2R positive cells were more sensitive
(4-75-fold) than E2R negative ones to growth-inhibiting
effects of TMX. Taken together with the conclusions of
Briand & Lykkesfeldt (1984) and those of Taylor et al.
(1984), the present data are compatible with a unified
concept postulating differential effects of TMX and
metabolites according to a concentration threshold. In the
present work and according to the type of drug considered,
this threshold was located between 2xlO-6 and 10-5M.
Below this level, TMX and metabolites would act primarily
through the E2R system by exerting a cytostatic effect; above
this level, a less specific, E2R independent, cytotoxic effect
would be implicated. The pharmacokinetic data reported
here indicate that, at the steady state, total plasmatic
concentrations of TMX plus metabolites are highly variable
in this range of 2 x 10-6M (Table I). Thus, during standard
TMX treatment (30mg daily) or alternative dosage (20 or
40mg daily) it is conceivable that both E2R specific and E2R
independent mechanisms may be implicated in the overall
expression of drug activity. We thus feel it could be of
interest to know, in a larger patient sample than in our
study, whether response (or stable disease) in E2R negative
patients could be related to high drug levels in plasma. It is
thus not surprising that recent studies on TMX concluded
that the benefit of TMX is independent of E2R status (Baum
& Nato, 1985) and that others considered that response to
endocrine therapy is only a facet of the generally favourable
prognosis of E2R positive patients rather than the sole
explanation (Shek et al., 1987).
At the same total concentration, the in vitro comparison of
drug and metabolite mixtures at Dl and Css did not reveal a
striking difference in their respective effects on MCF-7 and
CAL-18 B. Thus reaching steady state, with its particular
drug profile, would not be pharmacologically decisive for the
anti-oestrogenic response. Moreover, in both E2R negative
and positive cell lines, we noted that drug mixtures Dl and
Css reduced cell proliferation as a function of drug
concentration in the medium. Although it has not been
demonstrated that a loading dose schedule would be better
than the conventional TMX protocol (Abram, 1987), these
pharmacological observations may comfort the thesis of
authors calling for such a loading dose on the basis of
pharmacokinetic arguments (Wilkinson et al., 1982), so that
efficient plasmatic levels would be reached quicker. On the
other hand, the existence of this dose-response relationship
in both E2R positive and negative cells may shed some light
on the controversial literature data concerming the efficiency
of high dose TMX (Manni & Arafah, 1981; Stewart et al.,
1982). Recently, Watkins (1988), increasing TMX dose to
90mg daily in post-menopausal patients with advanced
breast cancer progressing after standard dose, concluded that
this high dose regimen was a clinically useful and highly
acceptable approach. As a corollary, in one patient
presenting an E2R positive recurrence during long-term
TMX therapy, Jordan et al. (1987) noted serum levels of
TMX and metabolites declining in the year prior to
recurrence.
We examined serum levels of TMX and metabolites with
regard to treatment response. The strict selection of patients
led to a limited group of 13 patients. On this set, no
significant correlation between treatment response and TMX
and/or metabolite individual serum levels was found.
Although 4-OHT appears to be the more potent drug tested
in vitro on E2R positive cells, its plasma levels at steady state
had never exceeded 69nM and this patient did not respond
to treatment. Moreover, in our total set of 78 patients, mean
concentration of 4-OHT was 5+10 nm. These levels of 4-
OHT are very low to expect an antiproliferative effect,
particularly on E2R negative tumours. Thus, from the
present data it does not seem possible to draw conclusions
on the importance of TMX metabolism in overall response
in vivo. However, new anti-oestrogenic compounds have
recently been developed on the basis of the 4-OHT structure,
e.g. the promising 3-OH TMX (Loser et al., 1985). Another
potential approach would be to stimulate, by appropriate
drug associations in vivo, the conversion of TMX in its more
efficient hydroxylated form. This could be theoretically
achievaJ,le when the enzymatic systems that process TMX
and metabolites have been elucidated. The hitherto unknown
biotransformation of metabolite Z in Y that we observed in
the presence of tumour cells may also stimulate such future
investigations.
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